Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13947285 | 0.83 | HDAC1 (0.79) | HDAC1HTTHPGDALDH1A1LMNA | |
| SCHEMBL13947519 | 0.82 | EPHX2 (0.66) | HDAC1HTTHPGDALDH1A1PPARG | |
| SCHEMBL13167369 | 0.80 | LIPG (0.49) | HTTHPGDALDH1A1POLBMEN1 | |
| SCHEMBL16127844 | 0.79 | HPGD (0.57) | HTTHPGDALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL13947127 | 0.77 | HPGD (0.64) | HTTHPGDALDH1A1LMNAPOLB | |
| SCHEMBL16088694 | 0.77 | HTT (0.58) | HTTHPGDALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL5213976 | 0.77 | POLB (0.49) | HDAC1HPGDPOLBSMN1; SMN2RAB9A | |
| SCHEMBL14817978 | 0.76 | ALDH1A1 (0.59) | HDAC1HTTHPGDALDH1A1MAPK14 | |
| SCHEMBL13947576 | 0.76 | ALDH1A1 (0.59) | HDAC1HTTHPGDALDH1A1MAPK14 | |
| SCHEMBL13947362 | 0.76 | LMNA (0.68) | HTTALDH1A1EPHX2MAPK14LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029990-A1 | Dihydropteridinones in the treatment of respiratory diseases | MAIER UDO | 2009-01-29 | — | — | US | disclosed |
| US-20070043055-A1 | Dihydropteridinones in the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043055-A1 | Dihydropteridinones in the treatment of respiratory diseases | QDPR, DHPS, NDUFS6 | HDAC1 4328/4885HTT 616/4885HPGD 59/4885 |
| US-20090029990-A1 | Dihydropteridinones in the treatment of respiratory diseases | QDPR, DHPS, NDUFS6 | HDAC1 4328/4885HTT 616/4885HPGD 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.